Expression of novel molecules, MICAL2-PV (MICAL2 prostate cancer variants), increases with high gleason score and prostate cancer progression

Clinical Cancer Research

Volumn 12, Issue 9, 2006, Pages 2767-2773

  Ashida, Shingo ^a,b   Furihata, Mutsuo ^b   Katagiri, Toyomasa ^a   Tamura, Kenji ^a,b   Anazawa, Yoshio ^a   Yoshioka, Hiroki ^a   Miki, Tsuneharu ^c   Fujioka, Tomoaki ^d   Shuin, Taro ^b   Nakamura, Yusuke ^a   Nakagawa, Hidewaki ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b KOCHI MEDICAL SCHOOL   (Japan)

^c KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^d IWATE MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; PROTEIN; PROTEIN MICAL 2 PV; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER GROWTH; CELL VIABILITY; CONTROLLED STUDY; CYTOPLASM; DNA MICROARRAY; GLEASON SCORE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LASER MICRODISSECTION; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; PROTEIN EXPRESSION; STAINING; STATISTICAL ANALYSIS; TISSUE MICROARRAY; TUMOR CLASSIFICATION;

ALTERNATIVE SPLICING; BASE SEQUENCE; CELL LINE, TUMOR; CYTOSKELETAL PROTEINS; DISEASE PROGRESSION; DNA PRIMERS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; PROSTATIC NEOPLASMS; VARIATION (GENETICS);

EID: 33646727564     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-1995     Document Type: Article

References (20)

1. Gronberg H. Prostate cancer epidemiology. Lancet 2003;361:859-64.
2. Han M, Partin AW, Piantadosi S, Epstein JI, Walsh PC. Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer. J Urol 2001;166:416-9.
3. Roberts SG, Blute ML, Bergstralh EJ, Slezak JM, Zincke H. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer. Mayo Clin Proc 2001;76:576-81.
4. Roberts WW, Bergstralh EJ, Blute ML, et al. Contemporary identification of patients at high risk of early prostate cancer recurrence after radical retropubic prostatectomy. Urology 2001;57:1033-7.
5. Ashida S, Nakagawa H, Katagiri T, et al. Molecular features of the transition from prostatic intraepithelial neoplasia (PIN) to prostate cancer: genome-wide gene-expression profiles of prostate cancers and PINs. Cancer Res 2004;64:5963-72.
6. Suzuki T, Nakamoto T, Ogawa S, et al. MICAL, a novel CasL interacting molecule, associates with vimentin. J Biol Chem 2002;277:14933-41.
7. Terman JR, Mao T, Pasterkamp RJ, Yu HH, Kolodkin AL. MICALs, a family of conserved flavoprotein oxidoreductases, function in plexin-mediated axonal repulsion. Cell 2002;109:887-900.
8. Trusolino L, Comoglio PM. Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nat Rev Cancer 2002;2:289-300.
9. Giordano S, Corso S, Conrotto P, et al. The semaphorin 4D receptor controls invasive growth by coupling with Met. Nat Cell Biol 2002;4:720-4.
10. Conrotto P, Corso S, Gamberini S, Comoglio PM, Giordano S. Interplay between scatter factor receptors and B plexins controls invasive growth. Oncogene 2004;23:5131-7.
11. Luo J, Zha S, Gage WR, et al. Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Res 2002;62:2220-6.
12. Anazawa Y, Nakagawa H, Furihata M, et al. PCOTH, a novel gene over-expressed in prostate cancers, promotes prostate cancer cell growth through phosphorylation of oncoprotein TAF-Iβ/SET. Cancer Res 2003;65:4578-86.
13. Stamey TA, Caldwell M, McNeal JE, Nolley R, Hemenez M, Downs J. The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? J Urol 2004;172:1297-301.
14. Pisters LL, Troncoso P, Zhau HE, Li W, von Eschenbach AC, Chung LW. c-Met proto-oncogene expression in benign and malignant human prostate tissues. J Urol 1995;154:293-8.
15. Knudsen BS, Gmyrek GA, Inra J, et al. High expression of the Met receptor in prostate cancer metastasis to bone. Urology 2002;60:1113-7.
16. Fischer J, Weide T, Barnekow A. The MICAL proteins and rab1: a possible link to the cytoskeleton? Biochem Biophys Res Commun 2005;328:415-23.
17. Winberg ML, Noordermeer JN, Tamagnone L, et al. Plexin A is a neuronal semaphorin receptor that controls axon guidance. Cell 1998;95:903-16.
18. Knudsen BS, Edlund M. Prostate cancer and the Met hepatocyte growth factor receptor. Adv Cancer Res 2004;91:31-67.
19. Kim SJ, Johnson M, Koterba K, Herynk MH, Uehara H, Gallick GE. Reduced c-Met expression by an adenovirus expressing a c-Met ribozyme inhibits tumorigenic growth and lymph node metastases of PC3-4 prostate tumor cells in an orthotopic nude mouse model. Clin Cancer Res 2003;9:5161-70.
20. Humphrey PA. Gleason grading and prognostic factors in carcinoma of the prostate. Mod Pathol 2004;17:292-306.